according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

Version Date of last issue: 10.10.2020 Revision Date: SDS Number: 5.0 09.04.2021 1842048-00009 Date of first issue: 19.07.2017

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name Betamethasone Ointment Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-: Pharmaceutical

stance/Mixture

1.3 Details of the supplier of the safety data sheet

Company Organon & Co.

30 Hudson Street, 33nd floor

07302 Jersey City, New Jersey, U.S.A

Telephone 551-430-6000

E-mail address of person responsible for the SDS

EHSSTEWARD@organon.com

1.4 Emergency telephone number

215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1B H360D: May damage the unborn child. Specific target organ toxicity - repeated H372: Causes damage to organs through pro-

exposure, Category 1 longed or repeated exposure.

Long-term (chronic) aquatic hazard, Cat-H410: Very toxic to aquatic life with long lasting

egory 1 effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms



Signal word Danger

Hazard statements H360D May damage the unborn child.

H372 Causes damage to organs through prolonged or re-

peated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements Prevention:

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 5.0
 09.04.2021
 1842048-00009
 Date of first issue: 19.07.2017

P201 Obtain special instructions before use.
P264 Wash skin thoroughly after handling.
P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protection/face protection

tion/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P391 Collect spillage.

Hazardous components which must be listed on the label: betamethasone

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Paraffin oil	8012-95-1 232-384-2	Asp. Tox. 1; H304 Aquatic Chronic 4; H413	>= 2,5 - < 10
betamethasone	378-44-9 206-825-4	Acute Tox. 2; H330 Repr. 1B; H360D STOT RE 1; H372 (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) Aquatic Chronic 1; H410 M-Factor (Chronic	>= 0,025 - < 0,1

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

Version	Revision Date: 09.04.2021	SDS Number:	Date of last issue: 10.10.2020
5.0		1842048-00009	Date of first issue: 19.07.2017
			aquatic toxicity): 1.000 specific concentration limit STOT RE 1; H372 >= 0,01 % Repr. 1B; H360D >= 0,01 %

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders First Aid responders should pay attention to self-protection,

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of contact, immediately flush skin with soap and plenty In case of skin contact

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks May damage the unborn child.

Causes damage to organs through prolonged or repeated

exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

Version Date of last issue: 10.10.2020 Revision Date: SDS Number: 5.0 09.04.2021 1842048-00009 Date of first issue: 19.07.2017

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Vapours may form explosive mixtures with air.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- : Carbon oxides

5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions Avoid release to the environment.

> Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 5.0
 09.04.2021
 1842048-00009
 Date of first issue: 19.07.2017

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust, fume, gas, mist, vapours or spray.

Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national

regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents Organic peroxides

Explosives Gases

7.3 Specific end use(s)

Specific use(s) : No data available

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 5.0 09.04.2021 1842048-00009 Date of first issue: 19.07.2017

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Petrolatum	8009-03-8	TWA (Vapour)	50 mg/m3	FOR-2011- 12-06-1358
		TWA (Mist and particles)	1 mg/m3	FOR-2011- 12-06-1358
Paraffin oil	8012-95-1	TWA (Vapour)	50 mg/m3	FOR-2011- 12-06-1358
		TWA (Mist and particles)	1 mg/m3	FOR-2011- 12-06-1358
betamethasone	378-44-9	TWA	1 μg/m3 (OEB 4)	Internal
	Further infor	Further information: Skin		
		Wipe limit	10 μg/100 cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health ef-	Value
			fects	
Paraffin oil	Workers	Inhalation	Long-term systemic effects	5 mg/m3
	Workers	Inhalation	Short-term exposure	5 mg/m3
	Workers	Inhalation	Long-term local ef- fects	5 mg/m3
	Workers	Inhalation	Acute local effects	5 mg/m3

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

	, , ,	• •
Substance name	Environmental Compartment	Value
Petrolatum	Oral (Secondary Poisoning)	9.33 ma/ka food

8.2 Exposure controls

Engineering measures

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

Personal protective equipment

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 5.0 09.04.2021 1842048-00009 Date of first issue: 19.07.2017

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Equipment should conform to NS EN 14387

Filter type : Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : ointment

Colour : No data available
Odour : No data available
Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range Flammability (solid, gas)

9

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

No data available

Not classified as a flammability hazard

Lower explosion limit / Lower

flammability limit

No data available

Flash point : > 93,3 °C

Auto-ignition temperature : No data available

Decomposition temperature

Decomposition tempera-

ture

No data available

pH : No data available

Viscosity

Viscosity, kinematic : Not applicable

Solubility(ies)

Water solubility : No data available

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 5.0
 09.04.2021
 1842048-00009
 Date of first issue: 19.07.2017

Partition coefficient: n-

octanol/water

: Not applicable

Vapour pressure : No data available

Relative density : No data available

Density : No data available

Relative vapour density : Not applicable

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : Not applicable

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Vapours may form explosive mixture with air.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Skin contact exposure Ingestion

Eye contact

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 5.0 09.04.2021 1842048-00009 Date of first issue: 19.07.2017

Acute toxicity

Not classified based on available information.

Components:

Paraffin oil:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Assessment: The substance or mixture has no acute dermal

toxicity

betamethasone:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

LD50 (Mouse): > 4.500 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0,4 mg/l

Exposure time: 4 h

Skin corrosion/irritation

Not classified based on available information.

Components:

Paraffin oil:

Species : Rabbit

Result : No skin irritation

betamethasone:

Species : Rabbit

Result : Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Paraffin oil:

Species : Rabbit

Result : No eye irritation

betamethasone:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 5.0
 09.04.2021
 1842048-00009
 Date of first issue: 19.07.2017

Respiratory sensitisation

Not classified based on available information.

Components:

betamethasone:

Exposure routes : Dermal
Species : Guinea pig
Result : Weak sensitizer

Germ cell mutagenicity

Not classified based on available information.

Components:

betamethasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse Application Route: Oral Result: equivocal

Germ cell mutagenicity- As-

sessment

: Weight of evidence does not support classification as a germ

cell mutagen.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

May damage the unborn child.

Components:

betamethasone:

Effects on foetal develop- : Species: Rabbit

ment Application Route: Intramuscular

Developmental Toxicity: LOAEL: 0,05 mg/kg body weight Result: Fetotoxicity, Malformations were observed.

Species: Rat

Application Route: Subcutaneous

Developmental Toxicity: LOAEL: 0,42 mg/kg body weight

Result: Malformations were observed.

Species: Mouse

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 5.0 09.04.2021 1842048-00009 Date of first issue: 19.07.2017

Application Route: Intramuscular

Developmental Toxicity: LOAEL: 1 mg/kg body weight

Result: Malformations were observed.

Reproductive toxicity - As-

sessment

: Clear evidence of adverse effects on development, based on

animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

Components:

betamethasone:

Target Organs : Pituitary gland, Immune system, muscle, thymus gland, Blood,

Adrenal gland

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Paraffin oil:

Species: Rat, femaleLOAEL: 161 mg/kgApplication Route: IngestionExposure time: 90 Days

betamethasone:

Species : Rabbit
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 10 - 30 d

Target Organs : Pituitary gland, Immune system, muscle

Species : Rat
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

Species : Mouse
LOAEL : 0.1 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

Species : Dog LOAEL : 0,05 mg/kg Application Route : Oral

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

Version Date of last issue: 10.10.2020 Revision Date: SDS Number: 5.0 09.04.2021 1842048-00009 Date of first issue: 19.07.2017

Exposure time 28 d

Target Organs Blood, thymus gland, Adrenal gland

Aspiration toxicity

Not classified based on available information.

Components:

Paraffin oil:

The substance or mixture is known to cause human aspiration toxicity hazards or has to be regarded as if it causes a human aspiration toxicity hazard.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

Experience with human exposure

Components:

betamethasone:

nhalation Target Organs: Adrenal gland

Symptoms: Redness, pruritis, Irritation

SECTION 12: Ecological information

12.1 Toxicity

plants

Components:

Paraffin oil:

Toxicity to fish : LL50 (Scophthalmus maximus (turbot)): > 100 mg/l

Exposure time: 96 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Toxicity to daphnia and other :

EL50 (Acartia tonsa): > 100 mg/l aquatic invertebrates

Exposure time: 48 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Toxicity to algae/aquatic

: EL50 (Skeletonema costatum (marine diatom)): > 100 mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 5.0
 09.04.2021
 1842048-00009
 Date of first issue: 19.07.2017

NOELR (Skeletonema costatum (marine diatom)): > 1 mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

betamethasone:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Americamysis): > 50 mg/l

Exposure time: 96 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 34

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 34

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC: 0,052 mg/l

Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

NOEC: 0,07 µg/l Exposure time: 219 d

Species: Oryzias latipes (Japanese medaka)

Method: OECD Test Guideline 229

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 8 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

M-Factor (Chronic aquatic : 1.000

toxicity)

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

Components:

Paraffin oil:

Partition coefficient: n- : log Pow: > 4

octanol/water Remarks: Calculation

betamethasone:

Partition coefficient: n-

octanol/water

log Pow: 2,11

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 5.0 09.04.2021 1842048-00009 Date of first issue: 19.07.2017

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Other adverse effects

Product:

Endocrine disrupting poten-

tial

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : UN 3077
ADR : UN 3077
RID : UN 3077
IMDG : UN 3077
IATA : UN 3077

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(betamethasone)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(betamethasone)

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 5.0
 09.04.2021
 1842048-00009
 Date of first issue: 19.07.2017

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(betamethasone)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(betamethasone)

IATA : Environmentally hazardous substance, solid, n.o.s.

(betamethasone)

14.3 Transport hazard class(es)

 ADN
 : 9

 ADR
 : 9

 RID
 : 9

 IMDG
 : 9

 IATA
 : 9

14.4 Packing group

ADN

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

ADR

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

IMDG

Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 956

aircraft)

Packing instruction (LQ) : Y956
Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen: 956

ger aircraft)

Packing instruction (LQ) : Y956

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

Version Date of last issue: 10.10.2020 Revision Date: SDS Number: 5.0 09.04.2021 1842048-00009 Date of first issue: 19.07.2017

Packing group

Labels Miscellaneous

14.5 Environmental hazards

 ΔDN

Environmentally hazardous yes

Environmentally hazardous yes

Environmentally hazardous yes

IMDG

Marine pollutant yes

IATA (Passenger)

Environmentally hazardous yes

IATA (Cargo)

Environmentally hazardous yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

: Not applicable for product as supplied. Remarks

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on

the market and use of certain dangerous substances.

preparations and articles (Annex XVII)

REACH - Candidate List of Substances of Very High Not applicable

Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation Not applicable

(Annex XIV)

Regulation (EC) No 1005/2009 on substances that de-Not applicable

plete the ozone layer

Regulation (EU) 2019/1021 on persistent organic pollu-Not applicable

tants (recast)

Regulation (EC) No 649/2012 of the European Parlia-Not applicable

ment and the Council concerning the export and import

of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of

major-accident hazards involving dangerous substances.

Quantity 1 Quantity 2 E1

ENVIRONMENTAL 100 t 200 t

Not applicable

HAZARDS

Other regulations:

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 5.0 09.04.2021 1842048-00009 Date of first issue: 19.07.2017

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Young people under the age of 18 are not allowed to use or be exposed to the product professionally. Young people above the age of 15 are, however, except from this rule if the product is a necessary part of their education.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H304 : May be fatal if swallowed and enters airways.

H330 : Fatal if inhaled.

H360D : May damage the unborn child.

H372 : Causes damage to organs through prolonged or repeated

exposure.

H410 : Very toxic to aquatic life with long lasting effects.
H413 : May cause long lasting harmful effects to aquatic life.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Chronic : Long-term (chronic) aquatic hazard

Asp. Tox. : Aspiration hazard Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

FOR-2011-12-06-1358 : Norway. Occupational Exposure limits

FOR-2011-12-06-1358 / : Long term exposure limit

TWA

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO

according to Regulation (EC) No. 1907/2006



Betamethasone Ointment Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 5.0
 09.04.2021
 1842048-00009
 Date of first issue: 19.07.2017

- International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA -Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sheet

Sources of key data used to compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:

Repr. 1B H360D Calculation method STOT RE 1 H372 Calculation method Aquatic Chronic 1 H410 Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN